1
|
Salcedo‐Bellido I, Requena P, Mateos R, Ortega‐Rico C, Olmedo‐Requena R, Lozano‐Lorca M, Arrebola JP, Barrios‐Rodríguez R. Factors associated with the development of second primary tumours in head and neck cancer patients. Eur J Cancer Care (Engl) 2022; 31:e13699. [PMID: 36117311 PMCID: PMC9787413 DOI: 10.1111/ecc.13699] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2022] [Revised: 07/15/2022] [Accepted: 08/31/2022] [Indexed: 12/30/2022]
Abstract
INTRODUCTION The development of second primary tumours (SPTs) is one of the main causes of low survival in patients with head and neck cancer (HNC). The aim of this study was to review the evidence about factors associated with developing SPTs in patients with HNC. METHODS An updated systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines, and the search was performed in Pubmed and Scopus. Only original articles with a cohort or case-control design were included. Article quality was assessed with the Newcastle-Ottawa scale. RESULTS Thirty-six and two case-control studies were included, with quality medium (n = 5) to high (n = 33). Tobacco showed a significant association with SPT development, with risks ranging from 1.41 (95%CI: 1.04-1.91) to 5.52 (95%CI: 2.91-10.49). Regarding alcohol, risks ranged from 1.46 (95%CI: 1.12-1.91) to 21.3 (95%CI: 2.9-156). Location of the index tumour in the hypopharynx/oropharynx, absence of human papillomavirus and presence of a premalignant lesion also increased the risk of SPTs. More controversy was found for sex, age and other clinical factors of the tumour. CONCLUSION Toxic lifestyle habits and clinical factors were associated with the risk of SPTs in HNC patients. These findings may improve individualised prevention strategies in its follow-up.
Collapse
Affiliation(s)
- Inmaculada Salcedo‐Bellido
- Departamento de Medicina Preventiva y Salud PúblicaUniversidad de GranadaGranadaSpain,Instituto de Investigación Biosanitaria de Granada (ibs.Granada)GranadaSpain,Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP)MadridSpain
| | - Pilar Requena
- Departamento de Medicina Preventiva y Salud PúblicaUniversidad de GranadaGranadaSpain,Instituto de Investigación Biosanitaria de Granada (ibs.Granada)GranadaSpain,Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP)MadridSpain
| | - Rocío Mateos
- Departamento de Medicina Preventiva y Salud PúblicaUniversidad de GranadaGranadaSpain
| | - Carmen Ortega‐Rico
- Departamento de Medicina Preventiva y Salud PúblicaUniversidad de GranadaGranadaSpain
| | - Rocío Olmedo‐Requena
- Departamento de Medicina Preventiva y Salud PúblicaUniversidad de GranadaGranadaSpain,Instituto de Investigación Biosanitaria de Granada (ibs.Granada)GranadaSpain,Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP)MadridSpain
| | - Macarena Lozano‐Lorca
- Departamento de Medicina Preventiva y Salud PúblicaUniversidad de GranadaGranadaSpain,Instituto de Investigación Biosanitaria de Granada (ibs.Granada)GranadaSpain
| | - Juan Pedro Arrebola
- Departamento de Medicina Preventiva y Salud PúblicaUniversidad de GranadaGranadaSpain,Instituto de Investigación Biosanitaria de Granada (ibs.Granada)GranadaSpain,Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP)MadridSpain
| | - Rocío Barrios‐Rodríguez
- Departamento de Medicina Preventiva y Salud PúblicaUniversidad de GranadaGranadaSpain,Instituto de Investigación Biosanitaria de Granada (ibs.Granada)GranadaSpain,Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP)MadridSpain
| |
Collapse
|
2
|
Tajiri A, Ishihara R, Sakurai H, Nakamura T, Tani Y, Inoue T, Matsueda K, Miyake M, Waki K, Fukuda H, Shichijo S, Maekawa A, Kanesaka T, Yamamoto S, Takeuchi Y, Higashino K, Uedo N, Michida T, Matsunaga T. Clinical features of superficial esophagus squamous cell carcinoma according to alcohol-degrading enzyme ADH1B and ALDH2 genotypes. J Gastroenterol 2022; 57:630-639. [PMID: 35788888 DOI: 10.1007/s00535-022-01892-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/02/2022] [Accepted: 06/06/2022] [Indexed: 02/04/2023]
Abstract
BACKGROUND Inactivated alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) are related to esophageal carcinogenesis. We aimed to clarify the clinical features associated with the alcohol-degrading enzyme genotypes, ADH1B and ALDH2. We also investigated the risk factors for metachronous esophageal squamous cell carcinoma (ESCC) and head and neck SCC (HNSCC). METHODS We conducted a single-center, retrospective study including patients with ESCC treated by endoscopic resection. Patients were recruited between October 2020 and September 2021. Buccal mucosal swabs were obtained from them to analyze the genetic polymorphisms affecting ADH (ADH1B) and ALDH (ALDH2) activity. Patients were categorized into three groups: both inactivated = double-inactivated group; inactivated ADH1B or ALDH2 = single-inactivated group; and both activated = activated group. RESULTS Among the 297 enrolled patients, patients in the double-inactivated group were significantly younger (P < 0.001) and 60% of them were ≤ 50 years old. This group also had more ESCCs located in the upper esophagus (P < 0.001) and more simultaneous multiple ESCCs (P = 0.044). More than half of the patients had multiple Lugol-voiding lesions (LVLs) (P < 0.001) and heavy alcohol consumers (P = 0.012). Metachronous ESCC and HNSCC were more common in the double-inactivated group (P < 0.001, P = 0.001). Multivariate analysis identified located in the upper esophagus, multiple LVLs and history of HNSCC as risk factors for metachronous ESCC. CONCLUSIONS Activation patterns of alcohol-metabolizing enzymes were related to age at ESCC onset, lesion location, and metachronous ESCC and HNSCC. Different approaches to the prophylaxis and treatment of esophageal cancer should be considered, depending on the enzyme activity pattern.
Collapse
Affiliation(s)
- Ayaka Tajiri
- Department of Gastrointestinal Oncology, Osaka International Cancer Institute, 1-69, Otemae 3-chome, Chuo-ku, Osaka, 541-8567, Japan
| | - Ryu Ishihara
- Department of Gastrointestinal Oncology, Osaka International Cancer Institute, 1-69, Otemae 3-chome, Chuo-ku, Osaka, 541-8567, Japan.
| | - Hirohisa Sakurai
- Department of Gastrointestinal Oncology, Osaka International Cancer Institute, 1-69, Otemae 3-chome, Chuo-ku, Osaka, 541-8567, Japan
| | - Takahiko Nakamura
- Department of Gastrointestinal Oncology, Osaka International Cancer Institute, 1-69, Otemae 3-chome, Chuo-ku, Osaka, 541-8567, Japan
| | - Yasuhiro Tani
- Department of Gastrointestinal Oncology, Osaka International Cancer Institute, 1-69, Otemae 3-chome, Chuo-ku, Osaka, 541-8567, Japan
| | - Takahiro Inoue
- Department of Gastrointestinal Oncology, Osaka International Cancer Institute, 1-69, Otemae 3-chome, Chuo-ku, Osaka, 541-8567, Japan
| | - Katsunori Matsueda
- Department of Gastrointestinal Oncology, Osaka International Cancer Institute, 1-69, Otemae 3-chome, Chuo-ku, Osaka, 541-8567, Japan
| | - Muneaki Miyake
- Department of Gastrointestinal Oncology, Osaka International Cancer Institute, 1-69, Otemae 3-chome, Chuo-ku, Osaka, 541-8567, Japan
| | - Kotaro Waki
- Department of Gastrointestinal Oncology, Osaka International Cancer Institute, 1-69, Otemae 3-chome, Chuo-ku, Osaka, 541-8567, Japan
| | - Hiromu Fukuda
- Department of Gastrointestinal Oncology, Osaka International Cancer Institute, 1-69, Otemae 3-chome, Chuo-ku, Osaka, 541-8567, Japan
| | - Satoki Shichijo
- Department of Gastrointestinal Oncology, Osaka International Cancer Institute, 1-69, Otemae 3-chome, Chuo-ku, Osaka, 541-8567, Japan
| | - Akira Maekawa
- Department of Gastrointestinal Oncology, Osaka International Cancer Institute, 1-69, Otemae 3-chome, Chuo-ku, Osaka, 541-8567, Japan
| | - Takashi Kanesaka
- Department of Gastrointestinal Oncology, Osaka International Cancer Institute, 1-69, Otemae 3-chome, Chuo-ku, Osaka, 541-8567, Japan
| | - Sachiko Yamamoto
- Department of Gastrointestinal Oncology, Osaka International Cancer Institute, 1-69, Otemae 3-chome, Chuo-ku, Osaka, 541-8567, Japan
| | - Yoji Takeuchi
- Department of Gastrointestinal Oncology, Osaka International Cancer Institute, 1-69, Otemae 3-chome, Chuo-ku, Osaka, 541-8567, Japan
| | - Koji Higashino
- Department of Gastrointestinal Oncology, Osaka International Cancer Institute, 1-69, Otemae 3-chome, Chuo-ku, Osaka, 541-8567, Japan
| | - Noriya Uedo
- Department of Gastrointestinal Oncology, Osaka International Cancer Institute, 1-69, Otemae 3-chome, Chuo-ku, Osaka, 541-8567, Japan
| | - Tomoki Michida
- Department of Gastrointestinal Oncology, Osaka International Cancer Institute, 1-69, Otemae 3-chome, Chuo-ku, Osaka, 541-8567, Japan
| | - Takashi Matsunaga
- Department of Medical Informatics, Osaka International Cancer Institute, 1-69, Otemae 3-chome, Chuo-ku, Osaka, 541-8567, Japan
| |
Collapse
|